Literature DB >> 16366816

Ever users versus never users of a "less risky" cigarette.

John R Hughes1, Josue P Keely, Peter W Callas.   

Abstract

The authors surveyed 173 smokers who purchased and 114 smokers who knew about but did not purchase Eclipse--a tobacco industry product that is advertised as a reduced risk cigarette. Most low-tar/nicotine cigarette users who purchased Eclipse believed Eclipse was safer than low-tar/nicotine cigarettes both for their own health (73%) and for the health of others around them (86%). Additionally, many viewed Eclipse as a step toward quitting (53%). The authors did not identify robust predictors of Eclipse use. At 6 months follow-up, Eclipse users were as likely to have tried to quit as nonusers; however, the small sample size does not rule out the possibility that Eclipse use undermines quit attempts. The authors conclude that almost all users believe Eclipse is safer than low-tar cigarettes. ((c) 2005 APA, all rights reserved).

Entities:  

Mesh:

Year:  2005        PMID: 16366816     DOI: 10.1037/0893-164X.19.4.439

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  7 in total

1.  Food and Drug Administration tobacco regulation and product judgments.

Authors:  Annette R Kaufman; Lila J Finney Rutten; Mark Parascandola; Kelly D Blake; Erik M Augustson
Journal:  Am J Prev Med       Date:  2015-02-25       Impact factor: 5.043

Review 2.  Postmarketing surveillance for "modified-risk" tobacco products.

Authors:  Richard J O'Connor
Journal:  Nicotine Tob Res       Date:  2011-01-20       Impact factor: 4.244

3.  Expanding clinical laboratory tobacco product evaluation methods to loose-leaf tobacco vaporizers.

Authors:  Alexa A Lopez; Marzena Hiler; Sarah Maloney; Thomas Eissenberg; Alison B Breland
Journal:  Drug Alcohol Depend       Date:  2016-10-11       Impact factor: 4.492

Review 4.  Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Authors:  Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 5.  Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods.

Authors:  Vaughan W Rees; Jennifer M Kreslake; K Michael Cummings; Richard J O'Connor; Dorothy K Hatsukami; Mark Parascandola; Peter G Shields; Gregory N Connolly
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 6.  Developing the science base for reducing tobacco harm.

Authors:  Dorothy K Hatsukami; Anne M Joseph; Mark Lesage; Joni Jensen; Sharon E Murphy; Paul R Pentel; Michael Kotlyar; Eugene Borgida; Chap Le; Stephen S Hecht
Journal:  Nicotine Tob Res       Date:  2007-11       Impact factor: 4.244

7.  Cigarette smokers' use of unconventional tobacco products and associations with quitting activity: findings from the ITC-4 U.S. cohort.

Authors:  Karin A Kasza; Maansi Bansal-Travers; Richard J O'Connor; Wilson M Compton; Anna Kettermann; Nicolette Borek; Geoffrey T Fong; K Michael Cummings; Andrew J Hyland
Journal:  Nicotine Tob Res       Date:  2013-12-27       Impact factor: 4.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.